Antibody binding specifically to CD66c and use thereof
The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.
1. An anti-CD66c (Cluster of Differentiation 66c) antibody or an antigen-binding fragment thereof, comprising the following complementarity determining regions (CDRs):
CDR-H1 comprising an amino acid sequence of SEQ ID NO: 1 or 9,
CDR-H2 comprising an amino acid sequence of SEQ ID NO: 2 or 10,
CDR-H3 comprising an amino acid sequence of SEQ ID NO: 3,
CDR-L1 comprising an amino acid sequence of SEQ ID NO: 4, 11 or 12,
CDR-L2 comprising an amino acid sequence of SEQ ID NO: 5 and
CDR-L3 comprising an amino acid sequence of SEQ ID NO: 6 or 13,
on the proviso that the antibody comprising CDRs consisting of amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 6 is not included.
2. The anti-CD66c antibody or an antigen-binding fragment thereof according to claim 1 , wherein the heavy chain variable region of the antibody comprises at least one selected from the group consisting of framework sequence (V-FR1) including the amino acid sequence of SEQ ID NO: 23, 24, 25, 26 or 27, framework sequence (V-FR2) including the amino acid sequence of SEQ ID NO: 33, 34, 35, 36 or 37, framework sequence (V-FR3) including the amino acid sequence of SEQ ID NO: 43, 44, 45, 46 or 47, and framework sequence (V-FR4) including the amino acid sequence of SEQ ID NO: 53, 54, 55, 56 or 57.
3. The anti-CD66c antibody or an antigen-binding fragment thereof according to claim 1 , wherein the light chain variable region of the antibody comprises at least one selected from the group consisting of framework sequence (L-FR1) including the amino acid sequence of SEQ ID NO: 29, 30 or 31, framework sequence (L-FR2) including the amino acid sequence of SEQ ID NO: 39, 40 or 41, framework sequence (L-FR3) including the amino acid sequence of SEQ ID NO: 49, 50, or 51, and framework sequence (L-FR4) including the amino acid sequence of SEQ ID NO: 59, 60 or 61.
4. The anti-CD66c antibody or an antigen-binding fragment thereof according to claim 1 , comprising a heavy chain variable region including the amino acid sequence of SEQ ID NO: 14, 15, 16, 17 or 18, and a light chain variable region including the amino acid sequence of SEQ ID NO: 19, 20, or 21.
5. The anti-CD66c antibody or an antigen-binding fragment thereof according to claim 1 , wherein the fluorescence variability of the antibody against ANS reagent is less than 200% at 62° C.
6. The anti-CD66c antibody or an antigen-binding fragment thereof according to claim 1 , wherein the antigen-binding fragment is scFv, (scFv)2, Fab, Fab′ or F(ab′) 2 of anti-CD66c antibody.
7. A method of treating a disease selected from cancer and cancer metastasis, comprising administering the anti-CD66c antibody or the antigen-binding fragment thereof according to claim 1 to a subject having cancer or cancer metastasis.
8. The method according to claim 7 , wherein the cancer is CD66c-positive solid cancer.
9. The method according to claim 8 , wherein the solid cancer is lung cancer, colon cancer, stomach cancer, liver cancer, breast cancer, or prostate cancer which are CD66c-positive.
10. The method according to claim 7 , further comprising administering an inhibitor of PD-1 or PD-L1 binding to the subject having cancer or cancer metastasis.
11. A nucleic acid molecule encoding the amino acid sequence of the heavy chain variable region selected from SEQ ID NOs:14, 15, 16, 17, and 18; encoding the amino acid sequence of the light chain variable region selected from SEQ ID NOs:19, 20, and 21; or encoding one of said heavy chain variable regions and one of said light chain variable regions.
12. A recombinant vector comprising the nucleic acid molecule according to claim 11 .
13. A recombinant cell comprising the recombinant vector according to claim 12 .